Jul. 15 at 9:22 PM
$ARDX Onoy 4-8-week trials? Hmm, without looking hard, there’s this from Nov. 22:
…..
"Notably, early response to XPHOZAH was found to be predictive of continued response throughout the treatment period. …..
New Clinical Analyses Being Presented by Ardelyx:
Poster # PO163 …..was based on a post hoc analysis of the Phase 3 PHREEDOM study evaluating if an early reduction in serum phosphorous (sP) following treatment with XPHOZAH would predict continued control of sP during subsequent treatment. Among patients who responded to XPHOZAH (>1.2 mg/dL decrease in sP from baseline) within the first month and remained on treatment, approximately 80% continued to have at least a 1.2 mg/dL decrease in sP from baseline during weeks 17-26 of the treatment period.
Poster # PO162 ….presented posthoc analyses of the two Phase 3 monotherapy studies BLOCK and PHREEDOM…Patients had clinically meaningful mean sP reductions…from baseline to the end of the randomized treatment periods or last assessment.”
